Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Timber Pharmaceuticals, Inc. | tmbr-20210630x10q.htm |
| EX-32.2 - EX-32.2 - Timber Pharmaceuticals, Inc. | tmbr-20210630xex32d2.htm |
| EX-31.2 - EX-31.2 - Timber Pharmaceuticals, Inc. | tmbr-20210630xex31d2.htm |
| EX-31.1 - EX-31.1 - Timber Pharmaceuticals, Inc. | tmbr-20210630xex31d1.htm |
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, John Koconis, Chief Executive Officer of Timber Pharmaceuticals, Inc. (the “Company”), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best of my knowledge, the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2021 (the “Report”) filed with the Securities and Exchange Commission:
·Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
· | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
| /s/ John Koconis |
|
| | John Koconis | |
| | Chief Executive Officer and Chairman of the Board of Directors | |
| | (Principal Executive Officer) | |
| | August 10, 2021 | |